Circulating vitamin E, transforming growth factor β1, and the association with renal disease susceptibility in two racial groups with type 2 diabetes

Kidney International

Volumn 67, Issue 5, 2005, Pages 1993-1998

  Zitouni, Karima ^a   Harry, Diane D ^a   Nourooz Zadeh, Jaffar ^a   Betteridge, D John ^a   Earle, Kenneth A ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; Hypertension; Oxidative stress; Renal function; TGF beta; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; CREATININE; LIPID HYDROPEROXIDE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAUCASIAN; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RACE DIFFERENCE; URINARY DIVERSION; VITAMIN BLOOD LEVEL;

EID: 17744396925     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00300.x     Document Type: Article

References (37)

1. STEPHENS GW, GILLAPSY JA, CLYNE D, et al: Racial differences in the incidence of end-stage renal disease in type I and II diabetes mellitus. Am J Kidney Dis 15:562-567, 1990
2. RODERICK PJ, RALEIGH VS, HALLAM L, MALLICK NP: The need and demand for renal replacement therapy amongst ethnic minorities in England. J Epidemiol Common Health 50:334-339, 1996
3. FEEHALY J, BURDEN AC, MAYBERRY JF, et al: Disease variations in Asians in Leicester. Q J Med 86:263-269, 1993
4. EARLE KA, MEHROTRA S, DALTON RN, et al: Defective nitric oxide production and functional renal reserve in patients with type 2 diabetes who have microalbuminuria of African and Asian compared with white origin. J Am Soc Nephrol 12:2125-2130, 2001
5. ONOZATO ML, TOJO A, GOTO A, et al: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACE1 and ARB. Kidney Int 61:186-194, 2002
6. OBROSOVA IG, FATHALLAH L, LIU E, NOUROOZ-ZADEH J: Early oxidative stress in the diabetic kidney: Effect of DL-a-lipoic acid. Free Rad Biol Med 34:186-195, 2003
7. ESTERBAUER H, DIEBER-ROTHENEDER M, STRIEGL G, WADEG G: Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am J Clin Nutr 53(Suppl 1):S314-S321, 1991
8. KOYA D, LEE IK, ISHII H, et al: Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol 8:426-435, 1997
9. LAL MA, KORNER A, MATSUO Y, et al: Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes 49:1381-1389, 2000
10. IGLESIAS-DE LA CRUZ MC, RUIZ-TORRES P, ALCAMI J, et al: Hydrogen peroxide increases extracellular matrix mRNA through TGF-beta in human mesangial cells. Kidney Int 59:87-95, 2001
11. 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 97:3479-3484, 2000
12. MEHROTRA S, LING KLE, BEKELY Y, et al: Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with type 2 diabetes mellitus. Diabet Med 18:109-115, 2001
13. COCKCROFT DW, GAULT MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
14. NOUROOZ-ZADEH J, TAJADDINI-SARMADI J, MCCARTHY S, et al: Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 54:1054-1058, 1995
15. NOUROOZ-ZADEH J, HALLIWELL B, TRITSSCHLER H, BETTERIDGE DJ: Decreased lipid standardised plasma α-tocopherol in non-insulin dependent diabetes mellitus. Diabetes und Stoffwechsel 6(Suppl 2):S20-S23, 1997
16. SHANG F, LU M, DUDEK E, et al: Vitamin C and vitamin E restore the resistance of GSH-depleted cells to H2O2. Free Rad Biol Med 34:521-530, 2003
17. CEBALLOS-PICOT I, WITKO-SARSAT V, MERAD-BOUDIA M, et al: Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Rad Biol Med 21:845-853, 1996
18. VAN DEN BRANDEN C, DEMAN A, CEYSSENS B, et al: Vitamin E protects renal antioxidant enzymes and attenuates glomerulosclerosis in adriamycin-treated rats. Nephron 91:129-133, 2002
19. CRAVEN PA, DERUBERTIS FR, KAGAN VE, et al: Effects of supplementation with vitamin C and E on albuminuria, glomerular TGF-beta, and glomerular size in diabetes. J Am Soc Nephrol 8:1405-1414, 1997
20. LEASK A, ABRAHAM DJ: TGF-beta signaling and the fibrotic response. FASEB J 18:816-827, 2004
21. FOGO AB: Renal fibrosis: Not just PAI-1 in the sky. J Clin Invest 112:326-328, 2003
22. YAMAMOTO T, NAKAMURA T, NOBLE NA, et al: Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814-1818, 1993
23. ZIYADEH FN, HUFFMAN BB, HAN DC, et al: Long term prevention of renal insufficiency, excess matrix gene expression by treatment with monoclonal anti-transforming growth factor-β antibody in db/db. Proc Natl Acad Sci USA 97:8015-5020, 2000
24. SUTHANTHIRAN M, KHANNA A, CUKRAN D, et al: Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients. Kidney Int 53:639-644, 1998
25. ISSHIKI K, HANEDA M, KOYA D, et al: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin sensitizing in diabetic rats. Diabetes 49:1022-1032
26. BIANCHI S, BIGAZZI R, CAIZZA A, CAMPESE VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41:565-570, 2003
27. WRIGHT JT, BAKRIS G, GREENE T et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 288:2421-2431, 2002
28. LEWIS EJ, HUNSICKER LG, BAIN RP, RHODE RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 2001
29. RAVID M, LANG R, RACHMANI R, LISHNER M: Long-term renoprotective effect of angiotensin-coverting enzyme inhibition in non-insulin dependent diabetes mellitus: A 7 year follow-up study. Arch Int Med 156:286-289, 1996
30. BRENNER BM, COOPER M, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
31. MANN JF, LONN EM, YI Q, GERSTEIN HC, et al: Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE study. Kidney Int 65:1375-80, 2004
32. LONN E, YUSUF S, HOOGWERF B, et al: Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25:27, 2002
33. BOAZ M, SMETANA S, WEINSTEIN T, et al: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 356:1213-1218, 2000
34. SARAN R, NOVAK JE, DESAI A, et al: Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): A pilot study. Nephrol Dial Transplant 18:2415-2420, 2003
35. SATO M, MATSUMOTO Y, MORITA H, et al: Effects of vitamin supplementation on microcirculatory disturbances in haemodialysis patients without peripheral arterial disease. Clin Nephrol 60:28-34, 2003
36. FORD ES, SOWELL A: Serum alpha-tocopherol status in the United States population: Findings from the Third National Health and Nutrition Examination survey. Am J Epidemiol 150:290-300, 1999
37. CHEN J, OGDEN LG, BATUMAN V, WHELTON PK: Relationship of serum antioxidant vitamins to serum creatinine in the US population. Am J Kidney Dis 39:460-468, 2002